Receptor/NN
for/IN
Advanced/JJ
Glycation/NN
Endproducts/NNS
(/(
RAGE/NN
)/)
,/,
Its/PRP$
Ligands/NNS
,/,
and/CC
Soluble/JJ
RAGE/NN
:/:
Potential/JJ
Biomarkers/NNS
for/IN
Diagnosis/NN
and/CC
Therapeutic/JJ
Targets/NNS
for/IN
Human/JJ
Renal/JJ
Diseases/NNS
./.
====================
Receptor/NN
for/IN
advanced/JJ
glycation/NN
endproducts/NNS
(/(
RAGE/NN
)/)
is/VBZ
a/DT
multi-ligand/JJ
receptor/NN
that/WDT
is/VBZ
able/JJ
to/TO
bind/VB
several/JJ
different/JJ
ligands/NNS
,/,
including/VBG
advanced/JJ
glycation/NN
endproducts/NNS
,/,
high-mobility/JJ
group/NN
protein/NN
(/(
B/NN
)/)
1/CD
(/(
HMGB1/NN
)/)
,/,
S-100/NN
calcium-binding/JJ
protein/NN
,/,
amyloid-β-protein/NN
,/,
Mac-1/NN
,/,
and/CC
phosphatidylserine/NN
./.
====================
Its/PRP$
interaction/NN
is/VBZ
engaged/VBN
in/IN
critical/JJ
cellular/JJ
processes/NNS
,/,
such/JJ
as/IN
inflammation/NN
,/,
proliferation/NN
,/,
apoptosis/NN
,/,
autophagy/NN
,/,
and/CC
migration/NN
,/,
and/CC
dysregulation/NN
of/IN
RAGE/NN
and/CC
its/PRP$
ligands/NNS
leads/VBZ
to/TO
the/DT
development/NN
of/IN
numerous/JJ
human/JJ
diseases/NNS
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
summarize/VBP
the/DT
signaling/NN
pathways/NNS
regulated/VBN
by/IN
RAGE/NN
and/CC
its/PRP$
ligands/NNS
identified/VBN
up/IN
to/TO
date/NN
and/CC
demonstrate/VBP
the/DT
effects/NNS
of/IN
hyper-activation/NN
of/IN
RAGE/NN
signals/NNS
on/IN
human/JJ
diseases/NNS
,/,
focused/VBN
mainly/RB
on/IN
renal/JJ
disorders/NNS
./.
====================
Finally/RB
,/,
we/PRP
propose/VBP
that/IN
RAGE/NN
and/CC
its/PRP$
ligands/NNS
are/VBP
the/DT
potential/JJ
targets/NNS
for/IN
the/DT
diagnosis/NN
,/,
monitoring/VBG
,/,
and/CC
treatment/NN
of/IN
numerous/JJ
renal/JJ
diseases/NNS
./.
====================
Receptor/NN
for/IN
advanced/JJ
glycation/NN
endproducts/NNS
(/(
RAGE/NN
)/)
is/VBZ
a/DT
transmembrane/JJ
protein/NN
that/WDT
belongs/VBZ
to/TO
the/DT
immunoglobulin/NN
superfamily/NN
[/(
1/CD
]/)
./.
====================
As/IN
its/PRP$
name/NN
implicates/VBZ
,/,
it/PRP
can/MD
bind/VB
to/TO
advanced/JJ
glycation/NN
endproducts/NNS
,/,
the/DT
resulting/VBG
product/NN
of/IN
non-enzymatic/JJ
glycosylation/NN
[/(
2/CD
]/)
,/,
and/CC
it/PRP
also/RB
has/VBZ
the/DT
ability/NN
to/TO
interact/VB
with/IN
multiple/JJ
ligands/NNS
having/VBG
common/JJ
motifs/NNS
as/IN
a/DT
so-called/JJ
multi-ligand/JJ
receptor/NN
./.
====================
The/DT
ligands/NNS
include/VBP
high-mobility/NN
group/NN
protein/NN
(/(
B/NN
)/)
1/CD
(/(
HMGB1/NN
)/)
,/,
S-100/NN
calcium-binding/JJ
protein/NN
,/,
amyloid-β-protein/NN
,/,
Mac-1/NN
,/,
and/CC
phosphatidylserine/NN
[/(
3/CD
]/)
./.
====================
Interaction/NN
between/IN
RAGE/NN
and/CC
its/PRP$
ligands/NNS
activates/VBZ
various/JJ
cellular/JJ
processes/NNS
,/,
including/VBG
inflammation/NN
,/,
proliferation/NN
,/,
apoptosis/NN
,/,
autophagy/NN
,/,
and/CC
migration/NN
[/(
4/CD
]/)
./.
====================
Expression/NN
of/IN
RAGE/NN
is/VBZ
different/JJ
,/,
depending/VBG
on/IN
the/DT
organ/NN
,/,
developmental/JJ
stage/NN
,/,
and/CC
cellular/JJ
condition/NN
[/(
5/CD
]/)
./.
====================
It/PRP
is/VBZ
highly/RB
expressed/VBN
during/IN
the/DT
embryonic/JJ
stage/NN
,/,
whereas/IN
it/PRP
is/VBZ
mostly/RB
kept/IN
at/IN
low/JJ
levels/NNS
in/IN
adults/NNS
[/(
5/CD
,/,
6/CD
]/)
./.
====================
Mostly/RB
,/,
it/PRP
is/VBZ
stimulated/VBN
by/IN
cellular/JJ
stresses/NNS
,/,
such/JJ
as/IN
inflammation/NN
,/,
and/CC
is/VBZ
therefore/RB
easily/RB
found/VBN
to/TO
be/VB
abnormally/RB
over-expressed/VBD
in/IN
many/JJ
human/JJ
chronic/JJ
diseases/NNS
[/(
7/CD
]/)
./.
====================
Accumulation/NN
of/IN
advanced/JJ
glycation/NN
endproducts/NNS
(/(
AGEs/NNS
)/)
is/VBZ
highly/RB
associated/VBN
with/IN
the/DT
pathogenesis/NN
of/IN
diabetes/NNS
,/,
which/WDT
causes/VBZ
serious/JJ
consequences/NNS
on/IN
metabolic/JJ
systems/NNS
[/(
8/CD
]/)
./.
====================
In/IN
addition/NN
,/,
expression/NN
of/IN
S100/NN
proteins/NNS
is/VBZ
reported/VBN
to/TO
be/VB
involved/VBN
in/IN
many/JJ
cancers/NNS
,/,
including/VBG
breast/NN
,/,
lung/NN
,/,
kidney/NN
,/,
and/CC
thyroid/NN
cancers/NNS
./.
====================
Mostly/RB
,/,
their/PRP$
up-regulation/NN
promotes/VBZ
tumorigenesis/NN
by/IN
stimulating/VBG
metastasis/NN
through/IN
the/DT
activation/NN
of/IN
relevant/JJ
transcription/NN
factors/NNS
or/CC
by/IN
acting/VBG
as/IN
chemoattractants/NNS
[/(
9/CD
,/,
10/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
cancers/NNS
,/,
RAGE/NN
and/CC
its/PRP$
ligands/NNS
are/VBP
abnormally/RB
regulated/VBN
in/IN
various/JJ
types/NNS
of/IN
chronic/JJ
immune/JJ
diseases/NNS
,/,
such/JJ
as/IN
atherosclerosis/NN
,/,
Alzheimer/NN
disease/NN
,/,
and/CC
arthritis/NN
[/(
7/CD
]/)
./.
====================
Increasing/VBG
evidence/NN
demonstrates/VBZ
the/DT
critical/JJ
role/NN
of/IN
RAGE/NN
signaling/NN
in/IN
many/JJ
other/JJ
human/JJ
diseases/NNS
and/CC
suggests/VBZ
its/PRP$
stimulating/NN
factors/NNS
as/IN
potential/JJ
biomarkers/NNS
for/IN
diagnosis/NN
or/CC
therapy/NN
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
are/VBP
going/VBG
to/TO
summarize/VB
the/DT
RAGE/NN
signaling/NN
pathway/NN
and/CC
its/PRP$
contribution/NN
to/TO
the/DT
pathogenesis/NN
of/IN
human/JJ
diseases/NNS
,/,
focused/VBN
specifically/RB
on/IN
kidney/NN
diseases/NNS
./.
====================
Further/RB
,/,
we/PRP
propose/VBP
the/DT
possibility/NN
of/IN
using/VBG
RAGE/NN
and/CC
its/PRP$
ligands/NNS
as/IN
therapeutic/JJ
targets/NNS
./.
====================
Human/JJ
RAGE/NN
is/VBZ
encoded/VBN
by/IN
a/DT
gene/NN
located/JJ
on/IN
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
class/NN
III/CD
region/NN
on/IN
chromosome/NN
6/CD
[/(
11/CD
]/)
./.
====================
The/DT
mature/JJ
RAGE/NN
has/VBZ
three/CD
main/JJ
parts/NNS
,/,
consisting/VBG
of/IN
extracellular/JJ
,/,
transmembrane/JJ
,/,
and/CC
cytosolic/JJ
regions/NNS
./.
====================
The/DT
extracellular/JJ
region/NN
is/VBZ
composed/VBN
of/IN
one/CD
V-type/JJ
and/CC
two/CD
C-type/JJ
domains/NNS
,/,
and/CC
the/DT
V-type/JJ
domain/NN
is/VBZ
responsible/JJ
for/IN
interaction/NN
with/IN
multiple/JJ
RAGE/NN
ligands/NNS
./.
====================
The/DT
transmembrane/JJ
domain/NN
anchors/NNS
RAGE/NN
to/TO
the/DT
cellular/JJ
membrane/NN
,/,
and/CC
signals/NNS
transduce/VBP
into/IN
the/DT
cell/NN
via/IN
the/DT
cytosolic/JJ
domain/NN
[/(
1/CD
,/,
12/CD
]/)
./.
====================
Besides/RB
,/,
RAGE/NN
variants/NNS
,/,
represented/VBN
by/IN
three/CD
forms/NNS
,/,
called/VBN
N-truncated/JJ
,/,
dominant-negative/JJ
,/,
and/CC
soluble/JJ
RAGE/NN
,/,
can/MD
be/VB
generated/VBN
either/CC
by/IN
natural/JJ
alternative/JJ
splicing/NN
or/CC
by/IN
the/DT
action/NN
of/IN
membrane-associated/JJ
proteases/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
[/(
1/CD
]/)
./.
====================
The/DT
N-truncated/JJ
form/VBP
of/IN
RAGE/NN
lacks/VBZ
a/DT
V-domain/JJ
so/RB
that/IN
it/PRP
can/MD
not/RB
interact/VB
with/IN
ligands/NNS
,/,
whereas/IN
the/DT
cytosolic/JJ
domain/NN
is/VBZ
missing/JJ
in/IN
dominant-negative/JJ
RAGE/NN
,/,
which/WDT
results/VBZ
in/IN
no/DT
signal/NN
transduction/NN
,/,
though/IN
it/PRP
can/MD
bind/VB
to/TO
ligands/NNS
./.
====================
Without/IN
the/DT
transmembrane/JJ
domain/NN
,/,
soluble/JJ
RAGE/NN
is/VBZ
formed/VBN
and/CC
is/VBZ
able/JJ
to/TO
circulate/VB
out/IN
of/IN
the/DT
cell/NN
and/CC
act/VBP
as/IN
decoys/VBZ
by/IN
preventing/VBG
ligands/NNS
from/IN
binding/VBG
to/TO
RAGE/NN
[/(
13/CD
]/)
./.
====================
Therefore/RB
,/,
soluble/JJ
RAGE/NN
can/MD
neutralize/VB
the/DT
effect/NN
of/IN
RAGE/NN
ligands/NNS
,/,
and/CC
many/JJ
studies/NNS
have/VBP
suggested/VBN
that/IN
this/DT
function/NN
might/MD
be/VB
applied/VBN
to/TO
inhibition/NN
of/IN
RAGE/NN
signals/NNS
in/IN
human/JJ
diseases/NNS
[/(
14/CD
]/)
./.
====================
RAGE/NN
and/CC
its/PRP$
ligands/NNS
are/VBP
highly/RB
expressed/VBN
in/IN
developmental/JJ
stages/NNS
and/CC
enhance/VBP
survival/NN
of/IN
neurons/NNS
during/IN
development/NN
[/(
15/CD
]/)
./.
====================
After/IN
embryonic/JJ
development/NN
,/,
these/DT
genes/NNS
are/VBP
down-regulated/VBN
and/CC
kept/IN
a/DT
low/JJ
expression/NN
levels/NNS
during/IN
normal/JJ
life/NN
,/,
except/IN
for/IN
certain/JJ
conditions/NNS
,/,
such/JJ
as/IN
injury/NN
and/CC
aging/NN
[/(
15/CD
]/)
./.
====================
Interestingly/RB
,/,
unlike/IN
other/JJ
receptors/NNS
,/,
expression/NN
of/IN
RAGE/NN
is/VBZ
positively/RB
regulated/VBN
by/IN
its/PRP$
ligand/NN
stimulation/NN
,/,
which/WDT
means/NNS
that/DT
increasing/VBG
concentration/NN
of/IN
ligands/NNS
leads/VBZ
to/TO
up-regulation/NN
of/IN
RAGE/NN
./.
====================
So/RB
,/,
RAGE/NN
signals/NNS
are/VBP
accelerated/VBN
more/RBR
and/CC
more/RBR
by/IN
the/DT
accumulation/NN
of/IN
signal/NN
stimulants/NNS
[/(
16/CD
]/)
./.
====================
RAGE/NN
is/VBZ
found/VBN
on/IN
the/DT
cell/NN
surface/NN
of/IN
various/JJ
immune/JJ
cells/NNS
,/,
and/CC
most/JJS
of/IN
its/PRP$
ligands/NNS
are/VBP
mainly/RB
secreted/VBN
by/IN
immune/JJ
cells/NNS
,/,
including/VBG
macrophages/NNS
and/CC
dendritic/JJ
cells/NNS
;/:
therefore/RB
one/CD
of/IN
the/DT
major/JJ
roles/NNS
of/IN
RAGE/NN
is/VBZ
involved/VBN
in/IN
inflammation/NN
[/(
7/CD
,/,
14/CD
]/)
./.
====================
Stimulation/NN
of/IN
RAGE/NN
by/IN
its/PRP$
ligands/NNS
activates/VBZ
the/DT
proinflammatory/JJ
transcription/NN
factor/NN
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-κB/NN
)/)
,/,
and/CC
it/PRP
then/RB
translocates/VBZ
into/IN
the/DT
nucleus/NN
and/CC
activates/VBZ
its/PRP$
target/NN
genes/NNS
,/,
including/VBG
several/JJ
kinds/NNS
of/IN
cytokines/NNS
responsible/JJ
for/IN
innate/JJ
or/CC
adaptive/JJ
immunity/NN
[/(
17/CD
,/,
18/CD
]/)
./.
====================
Also/RB
,/,
NF-κB/NN
can/MD
bind/VB
to/TO
glyoxalase/NN
(/(
Glo1/NN
)/)
and/CC
suppress/VBP
its/PRP$
inhibitory/JJ
activity/NN
on/IN
AGE/NN
production/NN
[/(
19/CD
]/)
./.
====================
Target/NN
genes/NNS
of/IN
NF-κB/NN
include/VBP
anti-apoptotic/JJ
genes/NNS
,/,
such/JJ
as/IN
Bcl/JJ
proteins/NNS
;/:
therefore/RB
,/,
cell/NN
survival/NN
is/VBZ
also/RB
under/IN
the/DT
control/NN
of/IN
NF-κB/NN
[/(
16/CD
]/)
./.
====================
In/IN
addition/NN
,/,
the/DT
mitogen-activated/JJ
protein/NN
kinase/NN
signaling/NN
pathway/NN
itself/PRP
can/MD
be/VB
activated/VBN
by/IN
RAGE/NN
stimulation/NN
./.
====================
Specifically/RB
,/,
activated/VBN
RAGE/NN
is/VBZ
able/JJ
to/TO
stimulate/VB
ERK/NN
,/,
p38/NN
,/,
and/CC
JNK/NN
,/,
and/CC
it/PRP
leads/VBZ
to/TO
induction/NN
of/IN
cell/NN
proliferation/NN
[/(
20/CD
]/)
./.
====================
Another/DT
process/NN
involved/VBN
in/IN
RAGE/NN
signaling/NN
is/VBZ
cell/NN
migration/NN
via/IN
transforming/VBG
growth/NN
factor/NN
beta/NN
(/(
TGF-β/NN
)/)
signal/NN
cascades/NNS
./.
====================
TGF-β/NN
is/VBZ
activated/VBN
by/IN
RAGE/NN
ligand/NN
stimulation/NN
and/CC
enhances/VBZ
its/PRP$
downstream/JJ
signals/NNS
./.
====================
They/PRP
include/VBP
the/DT
Ras/NN
homolog/NN
family/NN
and/CC
Rho-associated/JJ
kinase/NN
,/,
and/CC
activation/NN
of/IN
these/DT
genes/NNS
leads/VBZ
to/TO
stable/JJ
actin/NN
filament/JJ
formation/NN
and/CC
cell/NN
migration/NN
[/(
21/CD
]/)
./.
====================
Due/IN
to/TO
RAGE/NN
signals/NNS
being/VBG
concerned/VBN
with/IN
multiple/JJ
cellular/JJ
signaling/NN
pathways/NNS
,/,
in/IN
particular/JJ
with/IN
immune/JJ
responses/NNS
and/CC
cell/NN
survival/NN
,/,
the/DT
development/NN
of/IN
numerous/JJ
human/JJ
diseases/NNS
is/VBZ
associated/VBN
with/IN
it/PRP
./.
====================
They/PRP
include/VBP
diabetes/NNS
,/,
inflammatory/JJ
diseases/NNS
,/,
cancers/NNS
,/,
and/CC
cardiovascular/JJ
diseases/NNS
,/,
and/CC
blockade/NN
of/IN
RAGE/NN
is/VBZ
increasingly/RB
proposed/JJ
as/IN
a/DT
therapeutic/JJ
target/NN
[/(
4/CD
]/)
./.
====================
Expression/NN
of/IN
RAGE/NN
and/CC
its/PRP$
ligands/NNS
is/VBZ
kept/IN
at/IN
a/DT
low/JJ
level/NN
in/IN
a/DT
wide/JJ
range/NN
of/IN
cell/NN
types/NNS
,/,
including/VBG
endothelium/NN
,/,
smooth/JJ
muscle/NN
cells/NNS
,/,
mononuclear/JJ
phagocytes/NNS
,/,
neurons/NNS
,/,
and/CC
cardiac/JJ
myocytes/NNS
[/(
22/CD
]/)
./.
====================
However/RB
,/,
when/WRB
RAGE/NN
ligands/NNS
are/VBP
accumulated/VBN
by/IN
pathological/JJ
development/NN
of/IN
relevant/JJ
diseases/NNS
,/,
it/PRP
alters/VBZ
the/DT
structure/NN
of/IN
tissues/NNS
as/IN
well/RB
as/IN
compromise/RB
protein/NN
function/NN
in/IN
them/PRP
[/(
23/CD
,/,
24/CD
]/)
./.
====================
Also/RB
,/,
increased/VBD
circulating/VBG
RAGE/NN
ligands/NNS
induce/VBP
the/DT
expression/NN
of/IN
their/PRP$
receptor/NN
,/,
RAGE/NN
;/:
therefore/RB
,/,
RAGE/NN
ligand/NN
signals/NNS
are/VBP
stimulated/VBN
as/IN
the/DT
ligands/NNS
increase/VBP
[/(
16/CD
]/)
./.
====================
In/IN
kidneys/NNS
,/,
accumulation/NN
of/IN
RAGE/NN
ligands/NNS
is/VBZ
well/RB
studied/VBN
to/TO
contribute/VB
to/TO
both/CC
diabetic/JJ
and/CC
non-diabetic/JJ
nephropathy/NN
(/(
DN/JJ
)/)
./.
====================
Firstly/RB
,/,
AGEs/NNS
have/VBP
been/VBN
found/VBN
primarily/RB
to/TO
be/VB
up-regulated/VBN
in/IN
renal/JJ
basement/JJ
membranes/NNS
in/IN
diabetic/JJ
nephropathies/NNS
and/CC
in/IN
some/DT
other/JJ
renal/JJ
diseases/NNS
,/,
including/VBG
glomerulosclerosis/NN
and/CC
arteriosclerosis/NN
,/,
which/WDT
are/VBP
not/RB
related/JJ
to/TO
diabetes/NNS
[/(
25/CD
]/)
./.
====================
In/IN
diabetes/NNS
,/,
AGEs/NNS
are/VBP
highly/RB
accumulated/VBN
by/IN
increasing/VBG
mitochondrial/JJ
production/NN
of/IN
reactive/JJ
oxygen/NN
species/NNS
,/,
followed/VBN
by/IN
high/JJ
intracellular/JJ
glucose/NN
levels/NNS
[/(
26/CD
]/)
./.
====================
Abnormally/RB
high/JJ
concentrations/NNS
of/IN
AGEs/NNS
impair/VBP
proximal/JJ
tubular/JJ
cells/NNS
,/,
which/WDT
are/VBP
responsible/JJ
for/IN
regulation/NN
of/IN
AGE/NN
metabolism/NN
,/,
resulting/VBG
in/IN
damage/NN
to/TO
those/DT
cells/NNS
and/CC
their/PRP$
function/NN
[/(
27/CD
,/,
28/CD
]/)
./.
====================
Also/RB
,/,
kidneys/NNS
play/VBP
key/JJ
roles/NNS
in/IN
the/DT
clearance/NN
of/IN
AGEs/NNS
,/,
such/JJ
that/IN
the/DT
impaired/JJ
structure/NN
of/IN
the/DT
kidneys/NNS
by/IN
AGEs/NNS
fails/VBZ
to/TO
degrade/VB
them/PRP
[/(
29/CD
]/)
./.
====================
In/IN
turn/NN
,/,
more/RBR
and/CC
more/RBR
AGEs/NNS
are/VBP
accumulated/VBN
as/IN
the/DT
kidney/NN
is/VBZ
damaged/VBN
by/IN
the/DT
action/NN
of/IN
AGEs/NNS
,/,
and/CC
finally/RB
,/,
it/PRP
results/VBZ
in/IN
DN/JJ
[/(
27/CD
,/,
28/CD
,/,
30/CD
]/)
./.
====================
Recently/RB
,/,
increasing/VBG
evidence/NN
has/VBZ
shown/VBN
that/IN
RAGE/NN
ligands/NNS
other/JJ
than/IN
AGEs/NNS
,/,
including/VBG
HMGB1/NN
and/CC
S-100/NN
proteins/NNS
,/,
are/VBP
also/RB
up-regulated/VBD
in/IN
renal/JJ
diseases/NNS
./.
====================
HMGB1/NN
is/VBZ
a/DT
nuclear/JJ
protein/NN
essential/JJ
for/IN
regulating/VBG
the/DT
physical/JJ
interaction/NN
of/IN
DNA/NN
with/IN
certain/JJ
transcription/NN
factors/NNS
,/,
such/JJ
as/IN
p53/NN
[/(
29/CD
]/)
;/:
however/RB
,/,
when/WRB
it/PRP
is/VBZ
released/VBN
extracellularly/RB
,/,
it/PRP
is/VBZ
able/JJ
to/TO
mediate/VB
inflammatory/JJ
reactions/NNS
and/CC
contribute/VBP
to/TO
the/DT
pathogenesis/NN
of/IN
several/JJ
diseases/NNS
,/,
including/VBG
glomerulonephritis/NN
,/,
lupus/NN
nephritis/NN
,/,
and/CC
renal/JJ
cell/NN
carcinoma/NN
(/(
RCC/NN
)/)
[/(
31/CD
,/,
32/CD
]/)
./.
====================
In/IN
addition/NN
,/,
cell/NN
proliferation/NN
,/,
migration/NN
,/,
and/CC
invasion/NN
as/IN
well/RB
as/IN
inflammation/NN
are/VBP
also/RB
activated/VBD
in/IN
RCC/NN
via/IN
ERK1/2/NN
activation/NN
[/(
32/CD
]/)
./.
====================
Interaction/NN
between/IN
RAGE/NN
and/CC
its/PRP$
ligands/NNS
changes/NNS
renal/JJ
cellular/JJ
processes/NNS
,/,
including/VBG
inflammation/NN
,/,
proliferation/NN
,/,
and/CC
migration/NN
,/,
and/CC
they/PRP
are/VBP
highly/RB
significant/JJ
processes/NNS
to/TO
keep/VB
the/DT
normal/JJ
function/NN
of/IN
kidneys/NNS
;/:
therefore/RB
,/,
dysregulation/NN
of/IN
RAGE/NN
or/CC
its/PRP$
ligand/NN
concentrations/NNS
might/MD
give/VB
fatal/JJ
effects/NNS
,/,
leading/VBG
to/TO
the/DT
development/NN
and/CC
pathogenesis/NN
of/IN
renal/JJ
diseases/NNS
./.
====================
Diabetic/JJ
nephropathy/NN
====================
DN/JJ
is/VBZ
one/CD
of/IN
the/DT
diseases/NNS
triggered/VBN
by/IN
diabetes/NNS
and/CC
finally/RB
leads/VBZ
to/TO
renal/JJ
failure/NN
and/CC
elevation/NN
of/IN
arterial/JJ
blood/NN
pressure/NN
[/(
33/CD
]/)
./.
====================
Cellular/JJ
mechanisms/NNS
involved/VBN
in/IN
the/DT
development/NN
and/CC
pathogenesis/NN
of/IN
DN/JJ
include/VBP
glomerular/JJ
hypertrophy/NN
,/,
production/NN
of/IN
oxidative/JJ
stresses/NNS
,/,
fibrosis/NN
,/,
and/CC
inflammation/NN
,/,
followed/VBN
by/IN
hyperglycemia/NN
./.
====================
As/IN
mediators/NNS
,/,
renin/NN
,/,
angiotensin/NN
,/,
aldosterone/NN
,/,
protein/NN
kinases/NNS
,/,
and/CC
NADPH/NN
are/VBP
existing/VBG
,/,
and/CC
hyper-activation/NN
of/IN
them/PRP
results/VBZ
in/IN
up-regulation/NN
of/IN
fibrotic/JJ
and/CC
inflammatory/JJ
factors/NNS
,/,
including/VBG
TGF-β/NN
[/(
33-36/CD
]/)
./.
====================
Also/RB
,/,
hyperglycemia/NN
stimulates/VBZ
glycation/NN
and/CC
oxidation/NN
of/IN
macromolecules/NNS
,/,
which/WDT
result/VBP
in/IN
the/DT
formation/NN
of/IN
AGEs/NNS
as/IN
endproducts/NNS
[/(
37/CD
]/)
./.
====================
Accumulated/VBN
AGEs/NNS
join/NN
in/IN
the/DT
up-regulation/NN
of/IN
inflammatory/JJ
factors/NNS
and/CC
oxidative/JJ
stress/NN
and/CC
accelerate/VB
the/DT
pathogenesis/NN
of/IN
the/DT
disease/NN
[/(
38/CD
]/)
./.
====================
Cardio-renal/JJ
syndrome/NN
====================
Cardio-renal/JJ
syndrome/NN
is/VBZ
a/DT
combined/JJ
disorder/NN
having/VBG
both/CC
heart/NN
and/CC
kidney/NN
dysfunction/NN
./.
====================
The/DT
primary/JJ
failed/VBD
organ/NN
can/MD
be/VB
either/CC
the/DT
heart/NN
or/CC
kidney/NN
,/,
and/CC
in/IN
both/DT
cases/NNS
,/,
the/DT
one/CD
that/DT
is/VBZ
diseased/VBN
earlier/RBR
impairs/VBZ
the/DT
other/JJ
one/CD
,/,
and/CC
finally/RB
,/,
they/PRP
negatively/RB
affect/VB
each/DT
other/JJ
[/(
37/CD
]/)
./.
====================
One/CD
of/IN
the/DT
suggested/VBD
mechanisms/NNS
making/VBG
these/DT
two/CD
organs/NNS
negatively/RB
interact/VB
with/IN
each/DT
other/JJ
is/VBZ
mediated/VBN
by/IN
AGEs/NNS
[/(
39/CD
]/)
./.
====================
Accumulation/NN
of/IN
AGEs/NNS
is/VBZ
commonly/RB
observed/VBN
in/IN
patients/NNS
with/IN
both/CC
heart/NN
failure/NN
and/CC
renal/JJ
disorders/NNS
[/(
40/CD
,/,
41/CD
]/)
./.
====================
With/IN
heart/NN
failure/NN
,/,
increase/VBP
of/IN
AGEs/NNS
leads/VBZ
to/TO
inflammation/NN
,/,
fibrosis/NN
,/,
and/CC
delayed/VBD
calcium/NN
uptake/NN
,/,
which/WDT
subsequently/RB
result/NN
in/IN
diastolic/JJ
dysfunction/NN
./.
====================
In/IN
addition/NN
,/,
accumulation/NN
of/IN
AGEs/NNS
in/IN
renal/JJ
dysfunction/NN
is/VBZ
negatively/RB
affected/VBN
by/IN
highly/RB
activated/VBN
inflammation/NN
and/CC
fibrosis/NN
,/,
and/CC
further/RB
damage/NN
of/IN
kidney/NN
structure/NN
impairs/VBZ
its/PRP$
own/JJ
function/NN
of/IN
AGE/NN
clearance/NN
[/(
39/CD
]/)
./.
====================
Symptoms/NNS
of/IN
the/DT
disease/NN
might/MD
be/VB
enhanced/VBN
by/IN
this/DT
vicious/JJ
cycle/NN
,/,
as/IN
well/RB
as/IN
with/IN
other/JJ
multifactorial/JJ
signaling/NN
pathways/NNS
involved/VBN
in/IN
the/DT
pathogenesis/NN
./.
====================
Autosomal/JJ
dominant/JJ
polycystic/JJ
kidney/NN
disease/NN
====================
Autosomal/JJ
dominant/JJ
polycystic/JJ
kidney/NN
disease/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
highly/RB
prevalent/JJ
inherited/VBN
disorders/NNS
and/CC
is/VBZ
characterized/VBN
by/IN
the/DT
development/NN
of/IN
thousands/NNS
of/IN
epithelial-lined/JJ
,/,
fluid-filled/JJ
cysts/NNS
in/IN
the/DT
kidney/NN
[/(
42/CD
]/)
./.
====================
Cell/NN
proliferation/NN
,/,
inflammation/NN
,/,
and/CC
fibrosis/NN
are/VBP
the/DT
major/JJ
processes/NNS
of/IN
the/DT
development/NN
and/CC
pathogenesis/NN
of/IN
the/DT
disease/NN
,/,
and/CC
various/JJ
factors/NNS
,/,
including/VBG
chemokines/NNS
and/CC
growth/NN
factors/NNS
,/,
are/VBP
engaged/VBN
in/IN
these/DT
signaling/NN
pathways/NNS
[/(
43-45/CD
]/)
./.
====================
Recently/RB
,/,
several/JJ
studies/NNS
have/VBP
reported/VBN
that/IN
expression/NN
of/IN
HMGB1/NN
and/CC
certain/JJ
types/NNS
of/IN
S-100/NN
(/(
S-100A8/NN
,/,
9/CD
)/)
is/VBZ
increased/VBN
around/IN
the/DT
cystic/JJ
region/NN
and/CC
proposed/VBN
them/PRP
to/TO
be/VB
disease-stimulating/VBG
agents/NNS
[/(
46-48/CD
]/)
./.
====================
So/RB
,/,
inflammatory/JJ
and/CC
growth/NN
factors/NNS
secreted/VBN
by/IN
cyst-lined/JJ
epithelial/JJ
cells/NNS
and/CC
increased/VBD
circulating/VBG
AGEs/NNS
finally/RB
result/NN
in/IN
compromised/VBN
renal/JJ
function/NN
at/IN
the/DT
end/NN
stage/NN
of/IN
the/DT
disease/NN
./.
====================
Renal/JJ
cell/NN
carcinomas/NNS
====================
RAGE/NN
and/CC
its/PRP$
ligands/NNS
are/VBP
reported/VBN
to/TO
be/VB
abnormally/RB
expressed/VBD
in/IN
various/JJ
cancers/NNS
,/,
including/VBG
breast/NN
,/,
lung/NN
,/,
kidney/NN
,/,
thyroid/NN
,/,
prostate/NN
,/,
and/CC
oral/JJ
cancers/NNS
./.
====================
S100/NN
protein/NN
,/,
one/CD
of/IN
the/DT
representative/JJ
ligands/NNS
of/IN
RAGE/NN
,/,
which/WDT
has/VBZ
at/IN
least/JJS
over/IN
20/CD
subtypes/NNS
,/,
has/VBZ
been/VBN
well/RB
reviewed/VBN
to/TO
play/VB
major/JJ
roles/NNS
in/IN
tumor-related/JJ
processes/NNS
,/,
including/VBG
proliferation/NN
,/,
apoptosis/NN
,/,
metastasis/NN
,/,
and/CC
invasion/NN
[/(
10/CD
]/)
./.
====================
In/IN
renal/JJ
cancer/NN
,/,
S100A1/NN
has/VBZ
been/VBN
observed/VBN
to/TO
be/VB
highly/RB
expressed/VBN
in/IN
papillary/NN
RCC/NN
and/CC
oncocytoma/NN
,/,
which/WDT
are/VBP
relatively/RB
common/JJ
types/NNS
of/IN
renal/JJ
cancers/NNS
,/,
whereas/IN
it/PRP
is/VBZ
absent/JJ
in/IN
chromophobe/NN
RCC/NN
[/(
49/CD
]/)
./.
====================
Likewise/RB
,/,
a/DT
broad/JJ
range/NN
of/IN
S100/NN
proteins/NNS
has/VBZ
been/VBN
detected/VBN
differently/RB
,/,
depending/VBG
on/IN
the/DT
subtype/NN
of/IN
renal/JJ
carcinoma/NN
,/,
which/WDT
means/NNS
that/IN
it/PRP
should/MD
be/VB
a/DT
useful/JJ
biomarker/NN
for/IN
discriminating/VBG
the/DT
subtype/NN
of/IN
renal/JJ
cancers/NNS
if/IN
it/PRP
is/VBZ
correctly/RB
examined/VBN
[/(
50/CD
]/)
./.
====================
In/IN
addition/NN
,/,
HMGB1/NN
,/,
another/DT
ligand/NN
of/IN
RAGE/NN
,/,
has/VBZ
appeared/VBD
to/TO
be/VB
up-regulated/VBN
and/CC
interacts/VBZ
with/IN
its/PRP$
receptor/NN
for/IN
promoting/VBG
cell/NN
proliferation/NN
,/,
migration/NN
,/,
and/CC
invasion/NN
via/IN
the/DT
ERK/NN
pathway/NN
in/IN
RCC/NN
[/(
32/CD
]/)
./.
====================
From/IN
this/DT
evidence/NN
,/,
RAGE/NN
and/CC
its/PRP$
multiple/JJ
ligands/NNS
are/VBP
increasingly/RB
suggested/VBD
as/IN
biomarkers/NNS
and/CC
therapeutic/JJ
targets/NNS
for/IN
different/JJ
types/NNS
of/IN
renal/JJ
carcinomas/NNS
./.
====================
In/IN
various/JJ
types/NNS
of/IN
renal/JJ
diseases/NNS
,/,
including/VBG
both/CC
diabetic-/JJ
and/CC
non-diabetic/JJ
disorders/NNS
,/,
RAGE/NN
and/CC
its/PRP$
ligands/NNS
are/VBP
commonly/RB
observed/VBN
to/TO
be/VB
dysregulated/VBN
./.
====================
The/DT
major/JJ
problem/NN
of/IN
these/DT
phenomena/NNS
in/IN
renal/JJ
diseases/NNS
might/MD
be/VB
the/DT
vicious/JJ
cycle/NN
that/IN
impairs/VBZ
kidney/NN
by/IN
increased/VBN
AGEs/NNS
or/CC
when/WRB
other/JJ
RAGE/NN
ligands/NNS
fail/VBP
to/TO
remove/VB
them/PRP
,/,
causing/VBG
these/DT
ligands/NNS
to/TO
accumulate/VB
and/CC
the/DT
relevant/JJ
signals/NNS
to/TO
accelerate/VB
./.
====================
Therefore/RB
,/,
numerous/JJ
studies/NNS
suggest/VBP
RAGE/NN
and/CC
its/PRP$
ligands/NNS
as/IN
new/JJ
potential/JJ
targets/NNS
for/IN
the/DT
diagnosis/NN
,/,
monitoring/VBG
,/,
and/CC
treatment/NN
of/IN
renal/JJ
diseases/NNS
that/IN
have/VBP
abnormal/JJ
regulation/NN
of/IN
them/PRP
./.
====================
Firstly/RB
,/,
ligands/NNS
expression/NN
or/CC
secretion/NN
level/NN
can/MD
be/VB
used/VBN
as/IN
a/DT
diagnostic/JJ
or/CC
staging/NN
marker/NN
./.
====================
S100B/NN
is/VBZ
already/RB
used/VBN
in/IN
evaluations/NNS
after/IN
treatment/NN
of/IN
melanoma/NN
in/IN
a/DT
clinical/JJ
setting/VBG
[/(
51/CD
]/)
./.
====================
Secondly/RB
,/,
more/RBR
trials/NNS
targeting/VBG
RAGE/NN
ligands/NNS
either/CC
with/IN
inhibitors/NNS
of/IN
them/PRP
or/CC
the/DT
soluble/JJ
form/NN
of/IN
RAGE/NN
have/VBP
been/VBN
reported/VBN
./.
====================
Soluble/JJ
RAGE/NN
treatment/NN
significantly/RB
alleviates/VBZ
the/DT
symptoms/NNS
of/IN
nephritis/NN
in/IN
vivo/FW
[/(
52/CD
]/)
,/,
and/CC
in/IN
cancer/NN
studies/NNS
,/,
nude/JJ
mice/NNS
injected/VBD
with/IN
soluble/JJ
RAGE-over-expressing/NN
cells/NNS
have/VBP
shown/VBN
remarkable/JJ
inhibition/NN
of/IN
tumor/NN
formation/NN
[/(
53/CD
]/)
./.
====================
With/IN
inhibitors/NNS
of/IN
AGEs/NNS
,/,
several/JJ
agents/NNS
,/,
including/VBG
aminoguanidine/NN
and/CC
pyridoxamine/NN
,/,
have/VBP
been/VBN
tried/VBN
in/IN
humans/NNS
;/:
some/DT
of/IN
them/PRP
have/VBP
shown/VBN
enhanced/VBD
renal/JJ
function/NN
in/IN
diabetic/JJ
patients/NNS
,/,
but/CC
these/DT
trials/NNS
were/VBD
terminated/VBN
early/JJ
because/IN
of/IN
safety/NN
concerns/NNS
[/(
54/CD
,/,
55/CD
]/)
./.
====================
Finally/RB
,/,
more/RBR
recently/RB
,/,
epigenetic/JJ
regulation/NN
by/IN
microRNAs/NNS
of/IN
molecules/NNS
involved/VBN
in/IN
RAGE/NN
signaling/NN
pathways/NNS
is/VBZ
also/RB
being/VBG
studied/VBN
[/(
56/CD
]/)
./.
====================
Structures/NNS
of/IN
receptor/NN
for/IN
advanced/JJ
glycation/NN
end/NN
products/NNS
and/CC
its/PRP$
three/CD
main/JJ
isoforms/NNS
./.
====================
Full-length/JJ
receptor/NN
for/IN
advanced/JJ
glycation/NN
endproducts/NNS
(/(
RAGE/NN
)/)
has/VBZ
three/CD
different/JJ
extracellular/JJ
domains/NNS
(/(
V/JJ
,/,
C/NN
,/,
C/NN
'/``
)/)
and/CC
one/CD
cytosolic/JJ
domain/NN
./.
====================
Multi-ligands/NNS
bind/VBP
to/TO
the/DT
V-type/JJ
domain/NN
and/CC
transduce/VBP
signals/NNS
through/IN
the/DT
intracellular/JJ
domain/NN
./.
====================
The/DT
N-truncated/JJ
isoform/NN
lacks/VBZ
the/DT
V-type/JJ
domain/NN
,/,
which/WDT
fails/VBZ
to/TO
have/VB
receptor-ligand/JJ
interactions/NNS
./.
====================
The/DT
dominant-negative/JJ
form/NN
has/VBZ
no/DT
cytosolic/JJ
domain/NN
and/CC
is/VBZ
not/RB
able/JJ
to/TO
transduce/VB
signals/NNS
into/IN
the/DT
cell/NN
./.
====================
Soluble/JJ
RAGE/NN
is/VBZ
formed/VBN
either/CC
by/IN
alternative/JJ
splicing/NN
or/CC
protease/NN
activity/NN
and/CC
is/VBZ
secreted/VBN
and/CC
prevents/VBZ
ligands/NNS
from/IN
binding/VBG
to/TO
RAGE/NN
./.
====================
V/JJ
,/,
variable/JJ
domain/NN
;/:
C/NN
,/,
constant/JJ
domain/NN
./.
====================
